{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:20:16Z","timestamp":1791062416214,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.crohns.2012.02.007","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T12:30:49Z","timestamp":1330950649000},"page":"905-912","source":"Crossref","is-referenced-by-count":92,"title":["Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol"],"prefix":"10.1093","volume":"6","author":[{"given":"Melissa A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Marinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2012.02.007_bb0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2004.045294","article-title":"Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery","volume":"54","author":"Cosnes","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.02.007_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1126\/science.2649979","article-title":"The purine path to chemotherapy","volume":"244","author":"Elion","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.crohns.2012.02.007_bb0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0140-6736(93)91287-V","article-title":"Low-dose allopurinol plus azathioprine\/cyclosporin\/prednisolone, a novel immunosuppressive regimen","volume":"342","author":"Chocair","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2012.02.007_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00007691-199904000-00015","article-title":"Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine","volume":"21","author":"Chrzanowska","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.crohns.2012.02.007_bb0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.02.007_bb0055","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","article-title":"Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.007_bb0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.007_bb0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","article-title":"Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine","volume":"5","author":"Sparrow","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.02.007_bb0085","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2036.2009.04221.x","article-title":"Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease","volume":"31","author":"Ansari","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.007_bb0095","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/lt.20377","article-title":"Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation","volume":"11","author":"Breen","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.crohns.2012.02.007_bb0105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","article-title":"Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC","volume":"44","author":"Dervieux","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.crohns.2012.02.007_bb0115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2008.03788.x","article-title":"Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.007_bb0125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.02.007_bb0135","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.crohns.2012.02.007_bb0145","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.02.007_bb0155","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Prefontaine","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.crohns.2012.02.007_bb0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.HYP.35.3.746","article-title":"Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension","volume":"35","author":"Butler","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.crohns.2012.02.007_bb0175","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1081\/NCN-200027639","article-title":"Mutation in the ITPA gene predicts intolerance to azathioprine","volume":"23","author":"Marinaki","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.crohns.2012.02.007_bb0185","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2036.2008.03925.x","article-title":"Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease","volume":"29","author":"Hindorf","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.007_bb0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/14740330903571626","article-title":"Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease","volume":"9","author":"Korelitz","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.crohns.2012.02.007_bb0205","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?","volume":"49","author":"Lee","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.crohns.2012.02.007_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.crohns.2012.02.007_bb0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.crohns.2012.02.007_bb0235","article-title":"Cutaneous adverse drug reactions to allopurinol: 10year observational survey of the Dermatology Department \u2014 Cagliari University (Italy)","author":"Atzori","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"10.1016\/j.crohns.2012.02.007_bb0245","first-page":"Tu1214","article-title":"A biochemical mechanism for the role of allopurinol in TPMT inhibition","volume":"140","author":"Blaker","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.02.007_bb0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pbc.20089","article-title":"A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group)","volume":"43","author":"Bell","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.crohns.2012.02.007_bb0265","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.3748\/wjg.v17.i37.4166","article-title":"Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease","volume":"17","author":"Bradford","year":"2011","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/6\/9\/905\/7093867\/6-9-905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:48:54Z","timestamp":1593780534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2012.02.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1873994612000633"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2012.02.007","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}